LEADER 03048nam  22005175  450 
001 9910506387603321
005 20251113193513.0
010   $a3-030-79790-2
024 7 $a10.1007/978-3-030-79790-4
035   $a(CKB)5340000000068524
035   $a(MiAaPQ)EBC6789935
035   $a(Au-PeEL)EBL6789935
035   $a(OCoLC)1280461997
035   $a(PPN)258297719
035   $a(DE-He213)978-3-030-79790-4
035   $a(EXLCZ)995340000000068524
100   $a20211022d2021      u|         0
101 0 $aeng
135   $aur|z|||||||||
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 10$aNew Rapid-acting Antidepressants /$fedited by Kenji Hashimoto, Mario Manto
205   $a1st ed. 2021.
210  1$aCham :$cSpringer International Publishing :$cImprint: Springer,$d2021.
215   $a1 online resource (152 pages)
225 1 $aContemporary Clinical Neuroscience,$x2627-5341
300   $aIncludes index.
311 08$a3-030-79789-9 
327   $a(R)-ketamine: A new rapid-acting antidepressant -- (2R,6R)-hydroxynorketamine, a metabolite of ketamine: the antidepressant actions and the mechanisms -- Predictable biomarkers for rapid-acting antidepressant response to ketamine -- Nitrous Oxide: an old compound with emerging psychotropic properties -- Novel AMPA receptor potentiators TAK-137 and TAK-653 as potential rapid-acting antidepressants -- AMPA receptor potentiators as potential rapid-acting antidepressants -- mGlu2/3 receptor antagonists as rapid-acting antidepressants -- Antidepressant effects of the muscarinic receptor antagonist scopolamine: Clinical and preclinical review.
330   $aThis book discusses new candidates for rapid-acting antidepressants, such as (R)-ketamine, (2R,6R)-hydroxynorketamine, scopolamine, mGluR2/3 antagonists and AMPA receptor agonists. There are serious limitations to currently available antidepressants, such as delayed onset and low rates of efficacy. The discovery that a single dose of ketamine, an NMDAR antagonist, can produce rapid antidepressant effects that are sustained has led to new research in this area. In this volume, a variety of novel pharmaceutical treatments are examined. This volume would be useful to both researchers and clinicians who work in the field of pharmacology, specifically CNS drug treatments. Discusses new candidate for rapid-acting antidepressants Provides information for those who work in the field of CNS drugs Ideal for pharmacologists, psychiatrists, and those who want to learnabout CNS drugs at the graduate level.
410  0$aContemporary Clinical Neuroscience,$x2627-5341
606   $aNeurosciences
606   $aNeuroscience
615  0$aNeurosciences.
615 14$aNeuroscience.
676   $a616.8527061
702   $aHashimoto$b Kenji
702   $aManto$b Mario
801  0$bMiAaPQ
801  1$bMiAaPQ
801  2$bMiAaPQ
906   $aBOOK
912   $a9910506387603321
996   $aNew rapid-acting Antidepressants$92900064
997   $aUNINA